Anaheim Bio launches with €40 million Series A financing to advance ANA-1 for CPPD
The company said the oversubscribed €40 million Series A financing takes ANA-1 through IND-enabling studies and into Phase 1. Anaheim Bio, spun out of Alesta Therapeutics, expects clinic entry in 2027 and has a runway to 2028, with backing from Droia Ventures, Frazier Life Sciences, RTW, Novartis Venture Fund, RV Invest and Thuja Capital.
Primary source
Company press release (PR Newswire), November 5, 2026
Anaheim Bio Launches with €40 Million Series A Financing to Advance ANA-1 for Calcium Pyrophosphate Deposition Disease into the Clinic
Machine-summarized from the source above; not independently reported. How we use automation